Tuesday - March 24, 2026

Category Archives: Science

Why Trial-and-Error Is Dying: How Design of Experiments Training Is Eliminating Waste in Engineering

Design of Experiments Course by Excedify Excedify highlights the growing shift from trial-and-error engineering to structured experimentation through Design of Experiments (DOE) training. Companies adopting DOE reduce failed trials by up to 60%, cut development costs, and improve product quality. … Continue reading →

“The War Within,” a New Documentary Directed by Maya Segal, Follows U.S. Veterans Seeking Healing Through Ayahuasca in Cooperation with Forge and Harmonica Retreat

Still waters, deep wounds. “The War Within” — a documentary about U.S. veterans finding healing through ancient plant medicine in Colombia, facilitated by Harmonica Retreat and supported by Forge. Directed by Maya Segal. The War Within follows U.S. veterans with … Continue reading →

Cutaneous Lupus Erythematosus Clinical Trial Pipeline Accelerates as 10+ Pharma Companies Rigorously Develop Drugs for Market Entry | DelveInsight

DelveInsight’s, “Cutaneous Lupus Erythematosus Pipeline Insight 2026” report provides comprehensive insights about 10+ companies and 12+ pipeline drugs in Cutaneous Lupus Erythematosus pipeline landscape. It covers the Cutaneous Lupus Erythematosus Pipeline drug profiles, including clinical and nonclinical stage products. It … Continue reading →

HER2 Positive Breast Cancer Clinical Trial Pipeline Appears Robust With 50+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “HER2 Positive Breast Cancer Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in HER2 Positive Breast Cancer pipeline landscape. It covers the HER2 Positive Breast Cancer pipeline drug profiles, including clinical and nonclinical … Continue reading →

Acute Myeloid Leukemia Clinical Trial Pipeline Shows Potential with Active Contributions from 100+ Key Companies | DelveInsight

DelveInsight’s “Acute Myeloid Leukemia Pipeline Insights 2026” report provides comprehensive insights about 100+ companies and 110+ pipeline drugs in Acute Myeloid Leukemia pipeline landscape. It covers the Acute Myeloid Leukemia pipeline drug profiles, including Acute Myeloid Leukemia clinical trials and … Continue reading →

HDAC inhibitors Clinical Trial Pipeline Appears Robust With 40+ Key Pharma Companies Actively Working in the Domain | DelveInsight

DelveInsight’s, “HDAC Inhibitor Pipeline Insights 2026” report provides comprehensive insights about 40+ companies and 50+ pipeline drugs in HDAC Inhibitor pipeline landscape. It covers the HDAC Inhibitor pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Follicular Lymphoma Treatment Pipeline Shows Strong Momentum as 45+ Pharma Companies in the Race | DelveInsight

DelveInsight’s, “Follicular Lymphoma Pipeline Insight, 2026” report provides comprehensive insights about 45+ companies and 50+ pipeline drugs in Follicular Lymphoma pipeline landscape. It covers the Follicular Lymphoma pipeline drug profiles, including clinical and nonclinical stage products. It also covers the … Continue reading →

Esophageal Squamous Cell Carcinoma Clinical Trial Pipeline Shows Potential with Active Contributions from 50+ Key Companies | DelveInsight

DelveInsight’s, “Esophageal Squamous Cell Carcinoma Pipeline Insights 2026” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in Esophageal Squamous Cell Carcinoma pipeline landscape. It covers the Esophageal Squamous Cell Carcinoma pipeline drug profiles, including clinical and nonclinical … Continue reading →

Encephalopathy Clinical Trial Pipeline Gains Momentum: 50+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight

DelveInsight’s, “Encephalopathy Pipeline Insight, 2026” report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Encephalopathy pipeline landscape. It covers the Encephalopathy pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Encephalopathy pipeline therapeutics … Continue reading →